New program aims to boost HIV prevention pill use in eastern europe

NCT ID NCT05323123

Completed Prevention Sponsor: Columbia University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a program to help gay and bisexual men in Romania begin and continue taking PrEP, a daily pill that prevents HIV. The program combined in-person counseling, an educational app, and support from doctors. Researchers wanted to see if this approach was practical and effective in a region where PrEP is not widely used.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PrEP (pre-exposure prophylaxis) medication
What this could lead to: If successful, this program could help more men in Central-Eastern Europe access and use PrEP, reducing new HIV infections in the region.
What could go wrong: This was a small, early feasibility study (120 participants) in one country, so results may not apply broadly. The program's success depends on real-world healthcare systems and individual adherence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS Homosexuality HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HUMAN IMMUNODEFICIENCY VIRUS

Contacts and locations

Locations

Columbia University School of Nursing

New York, New York, 10032, United States
Romanian Association Against AIDS

Bucharest, Romania
Romanian Association Against AIDS

Cluj-Napoca, Romania

More trials for these conditions

Other studies related to the condition(s) this trial covers.